Company Overview
Immunic, Inc., a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical and phase 2 clinical development for patients with relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis. The company also develops IMU-856, which is entering Phase 2 clinical trial, for the restoration of the intestinal barrier function in patients suffering from gastrointestinal diseases, such as celiac disease, inflammatory bowel disease, short bowel syndrome, irritable bowel syndrome with diarrhea, and other intestinal barrier function diseases; and IMU-381, which is in preclinical trial, for the treatment of gastrointestinal diseases. Immunic, Inc. was founded in 2016 and is headquartered in New York, New York.
Growth & Price Performance
Stock Price Performance
| 1 Year: | +53.68% |
| 6 Months: | +1.92% |
| 3 Months: | +5.64% |
| 1 Month: | -10.91% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMAAbove
- RSI (14)33.00 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | IMUX Immunic, Inc. PHARMA | 12.74 | -3.59 | $173.83M | 0.00% | - | -138.17% | - | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2015 | Jun 2015 | Sep 2015 | Dec 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Income | -14.82M | -15.08M | -12.34M | - | -9.66M | -9.55M | -10.24M | -12.69M | -12.55M | -12.64M | - | -14.49M | -2.67M | -1.80M | - | -4.66M | -15.01M | -9.18M | - | -9.01M | -12.22M | -13.54M | - | -32.39M | -19.17M | -18.39M | - | -21.43M | -20.61M | -20.12M | -27.25M | -25.02M | -23.57M | -23.88M | -22.81M | -25.73M | -26.82M | -27.08M | -25.99M | -33.23M |
| Net Income | -14.76M | -15.11M | -12.30M | -9.86M | -9.59M | -9.47M | -10.18M | -12.60M | -12.41M | -12.48M | -14.59M | -2.26M | -2.67M | -1.80M | -4.81M | -4.31M | -14.71M | -8.21M | -7.69M | -8.49M | -11.46M | -12.91M | -11.16M | -34.53M | -17.93M | -19.29M | -21.18M | -20.81M | -21.90M | -21.22M | -25.27M | -24.00M | -22.77M | -29.58M | -21.38M | -24.37M | -25.47M | -26.82M | -25.58M | -32.59M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -0.79 | -0.90 | -0.70 | -0.53 | -1.63 | -0.82 | -0.76 | -0.81 | -0.74 | -0.72 | -0.69 | -0.58 | -0.54 | -0.51 | -0.30 | -0.21 | -0.24 | -2.51 | -0.20 | -0.13 | -1.08 |
| R&D Expense | 11.75M | 11.54M | 9.65M | - | 6.86M | 6.86M | 7.47M | 9.63M | 9.83M | 9.69M | - | 10.16M | 2.16M | 1.41M | - | 3.35M | 6.03M | 7.10M | - | 6.43M | 9.99M | 11.04M | - | 11.52M | 15.74M | 15.48M | - | 17.45M | 16.54M | 16.54M | 22.96M | 21.17M | 19.80M | 18.74M | 18.32M | 21.37M | 21.53M | 21.37M | 20.01M | 25.63M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Income | -9.58M | -31.40M | -50.34M | -52.12M | -41.27M | -52.66M | -12.00M | -37.03M | -48.97M | -91.67M | -119.49M | -99.22M | -98.05M | -103.23M |
| Net Income | -6.70M | -32.72M | -47.67M | -52.02M | -40.97M | -52.08M | -11.54M | -34.93M | -44.02M | -92.94M | -120.41M | -93.61M | -100.51M | -97.17M |
| Diluted EPS | - | - | - | - | - | - | - | - | -2.81 | -3.93 | -3.78 | -2.11 | -1.00 | -0.62 |
| R&D Expense | 5.10M | 21.79M | 39.48M | 39.77M | 30.05M | 39.34M | 9.60M | 22.51M | 38.64M | 61.12M | 71.25M | 83.22M | 80.05M | 81.98M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 46.59M | 108.08M | 89.08M | 64.03M | 60.38M | 13.37M | 65.95M | 167.86M | 139.10M | 127.75M | 54.30M | 40.87M | 24.05M |
| Total Equity | -54.85M | -7.63M | -44.66M | 97.56M | 82.33M | 58.45M | -13.34M | -25.74M | 58.36M | 158.78M | 127.11M | 113.68M | 28.93M | 18.43M | -6.67M |
| Cash & Equivalents | 803.00K | 4.48M | 38.19M | 102.24M | 83.42M | 59.99M | 56.90M | 13.07M | 29.37M | 127.45M | 86.86M | 106.75M | 46.67M | 35.67M | 15.48M |
| Total Liabilities | - | - | - | - | - | - | - | 1.92M | 7.59M | 9.08M | 11.98M | 14.07M | 25.37M | 22.44M | 30.73M |
| Current Liabilities | - | - | 7.45M | 10.28M | 6.66M | 5.48M | 10.28M | 1.92M | 7.07M | 8.40M | 11.40M | 13.08M | 24.73M | 22.18M | 30.62M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | -35.77M | -40.40M | -9.74M | -28.55M | -46.12M | -83.23M | -65.14M | -70.83M | -84.77M | -85.81M |
| Investing Cash Flow | - | - | - | - | -21.00K | -678.00K | -32.00K | 10.54M | -146.00K | -67.00K | -9.74M | 9.46M | -264.00K | -161.00K |
| Financing Cash Flow | - | - | - | - | 12.37M | 37.98M | 19.26M | 34.90M | 144.43M | 42.84M | 95.76M | 1.03M | 74.54M | 65.58M |
| Capital Expenditure | -261.00K | -1.48M | -1.41M | -2.34M | -556.00K | -685.00K | -32.00K | -55.00K | -146.00K | -67.00K | -112.00K | -334.00K | -264.00K | -161.00K |
| Free Cash Flow | - | - | - | - | -36.33M | -41.08M | -9.77M | -28.60M | -46.27M | -83.30M | -65.26M | -71.16M | -85.03M | -85.97M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| ROE % | 87.8% | 73.3% | -48.9% | -63.2% | -70.1% | 390.5% | 44.8% | -59.9% | -27.7% | -73.1% | -105.9% | -323.6% | -545.4% | 1,456.2% |
| ROCE % | - | -80.2% | -51.5% | -63.2% | -70.5% | -105.1% | -104.8% | -62.9% | -30.7% | -71.8% | -104.2% | -335.6% | -524.5% | 1,572.2% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Aberdeen Group plc | 6.04% | 824.39K | $8.76M |
| 2 | BVF Inc. | 5.61% | 765.29K | $8.13M |
| 3 | Millennium Management Llc | 5.43% | 740.35K | $7.86M |
| 4 | Avidity Partners Management, LP | 4.91% | 669.94K | $7.11M |
| 5 | Braidwell LP | 4.73% | 645.01K | $6.85M |
| 6 | Laurion Capital Management, LP | 4.47% | 610.33K | $6.48M |
| 7 | Vanguard Capital Management LLC | 4.19% | 571.56K | $6.07M |
| 8 | Jones Hill Capital LP | 3.96% | 539.81K | $5.73M |
| 9 | Woodline Partners LP | 3.46% | 471.53K | $5.01M |
| 10 | Soleus Capital Management, L.P. | 3.30% | 450.00K | $4.78M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for IMUX
Why Did IMUX Stock Surge 33% Pre-Market Today? - Stocktwits
<a href="https://news.google.com/rss/articles/CBMiqAFBVV95cUxNa2JaYmhkVlp1aUJJNnR6NFlkdUxDcTY3LVJBYXJ6ZjNfb094M1RZYTFuTXVQQmdpcVpqTjU4NldTY250eWIxaVhQN3FSY1UwSTlzSmtNd1VPUHhMNUNUWWJVZ290ZzZPZmIyRlZfUnRzWmZMdFlkZWhmeUNfd0t5Tzh2ejh6Mk5VTU5Wb2…
Immunic, Inc. Announces 1-for-10 Reverse Stock Split - PR Newswire
<a href="https://news.google.com/rss/articles/CBMiqgFBVV95cUxNbG1xN2FKT0dlWGlCeTFtek5famlZbXlXN2dkS1NDdVJ1NmE3VHJFblV0VlFkV2JkaFc3SmJCWDdGR250VXRjVTdZaDRQbGo2VjNXSDloeEpEMWg3RXJuQXBpQzMxb0M3WGNFZmpudl8wMXlyODlwODV1blhjeFJBc1hSQkZLQVlDcVdVRX…
Responsive Playbooks and the IMUX Inflection - Stock Traders Daily
<a href="https://news.google.com/rss/articles/CBMiwgFBVV95cUxOMndGVUpkaXRqOEM0V1pmVnNPYzNqbmxfd2RVQ0M1TnhuSERrNFMtV2JqYjlHYm9raHN6N0FEUW91UDgzemRsUUpQVm9feFVoVGtjQzM3cTZLbmFxMUNvOHNXMnVWSy03S25qc3VWUWNxLVVteUpBa0k3eGhEd1RCcUFSOGNfbDUzRU90eV…
Can Immunic (IMUX) Climb 163.03% to Reach the Level Wall Street Analysts Expect? - finance.yahoo.com
<a href="https://news.google.com/rss/articles/CBMilAFBVV95cUxOWUk5TXUxdDEwenNPb2VSOTRoSmIzVkdrZDBUNEJ1a1R5cjhrOFhhYlNwZkdvNERaSENtYm4yU2FhaW9FOUtxTTZqXy1tWEE4RGY2Y1ctNjVyb3Z0enh5QnhuVDFkSGVkcW1mN2hVeTN2RTllUG1Vck5yNlEtR1k0TnI2WG1CRXRTVS1WaU…
IMUX Forecast — Price Target — Prediction for 2027 - tradingview.com
<a href="https://news.google.com/rss/articles/CBMiekFVX3lxTFAyd3AwaEExSEszMl9Lb2FON0l1bnVnd29Dc181YTFlTHJwSVEwd09xcnFoZ2F1bEhiWkMwVW81aV9hX01yVUl1YXVWUUpVR0FqX01ZN0RNcTU0Y0NCR3lqUDk1dFdZa3BMVnlBcFpjZmxJNV9rRXIzd3JB?oc=5" target="_blank">IMU…
Biotech Immunic secures $200M to test oral multiple sclerosis drug - Stock Titan
<a href="https://news.google.com/rss/articles/CBMitgFBVV95cUxOMTVGaTlvVUNHXzFVazJyYks2OWRTdGZfRnhlVlE1cTZKV1otbDBXT2JBb3NMV2hWY1VRdXNhUlNuZGpVZ1hTREtBNEFGSTBITm1fLTEyVUVnR0l0UktMbGQzTFBRSFZoT2k0bENwNnpMUS1BSUZ5Vy1jWlFsZnVfbVJYNjZ2QU55OF9vM0…
IMUX — Frequently Asked Questions
What is the current share price of Immunic, Inc. (IMUX)?
As of 2026-09-19 21:16 PDT, Immunic, Inc. (IMUX) trades at $12.74 on NasdaqCM. Its 52-week range is $5.10 to $16.90.
What is the market capitalisation of IMUX?
Immunic, Inc. (IMUX) has a market capitalisation of $173.83M on NasdaqCM.
What is the P/E ratio of IMUX?
IMUX trades at a trailing price-to-earnings (P/E) ratio of -3.59. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 1.14.
What is the return on equity (ROE) of IMUX?
IMUX has a return on equity (ROE) of -138.17%.
Is IMUX a good stock to buy?
This page provides a data-driven analysis of Immunic, Inc. (IMUX), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.